Acquired Epidermolysis Bullosa (EB) is a rare, chronic, autoimmune disorder that affects the skin and mucous membranes. It is characterized by the formation of painful blisters and erosions on the skin, often triggered by minimal friction or trauma. This condition is distinct from the genetic forms of EB, as it develops later in life and is not inherited.
In acquired EB, the body's immune system mistakenly targets and attacks proteins that are essential for maintaining the integrity and strength of the skin layers. As a result, the layers of the skin become fragile and easily damaged. Blisters can appear in various areas of the body, including the hands, feet, joints, mucous membranes, and even internal organs.
Common symptoms of acquired EB include blistering, open sores, scarring, skin thickening, and nail abnormalities. In severe cases, complications such as infection, vision loss due to corneal damage, and difficulty swallowing or breathing may occur.
The exact cause of acquired EB is unknown, but it is believed to be related to an immune response triggered by certain medications, infections, or underlying autoimmune conditions. Diagnosis is typically made through a combination of clinical examination, skin biopsy, and immunological tests.
While there is no cure for acquired EB, treatment primarily focuses on managing symptoms and preventing complications. This may involve wound care, avoiding friction or trauma, controlling underlying autoimmune conditions, and using immunosuppressant medications to reduce the immune response.
Overall, acquired EB is a challenging and potentially debilitating condition that requires ongoing medical management and support to improve the quality of life of affected individuals.
